High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)
| Autor: | Janice Wahl, S. Jin, N. Gendrano, Frank J. Dutko, H.-C. Huang, E.J. Gane, H. Liu, M. Su, Eliav Barr, R. Plank, Jesper Bach Hansen, Ziv Ben Ari, Alex Lund Laursen, J. Bourque, S. Pianko, Bach-Yen Nguyen, Joan R. Butterton, A. Grandhi, Lawrence Serfaty, D. Fernsler, Wendy W. Yeh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Hepatology Gastroenterology & Hepatology business.industry Ribavirin Virology Gastroenterology Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Grazoprevir Chronic hepatitis 030220 oncology & carcinogenesis Virologic response Internal medicine Medicine 030211 gastroenterology & hepatology Crest In patient business Drug regimen |
| Zdroj: | Serfaty, L, Pianko, S, Ben Ari, Z, Laursen, A L, Hansen, J B, Gane, E J, Huang, H C, Jin, S, Bourque, J, Liu, H, Grandhi, A, Su, M, Gendrano, N, Fernsler, D, Dutko, F, Nguyen, B Y T, Wahl, J, Barr, E, Yeh, W, Plank, R & Butterton, J R 2017, ' High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2) ', Journal of Hepatology, vol. 66, no. 1, THU-264, pp. S306-S307 . https://doi.org/10.1016/S0168-8278(17)30931-5 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|